Skip to content

Madrigal Pharmaceuticals

US · MDGL #1355 by market cap Listed 2016
379.10 -17.64 -4.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Wells Fargo Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $685
    Market Newswire · 2026/10/12
  • Rating change
    Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962
    Market Newswire · 2026/11/4
  • Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $760
    Market Newswire · 2026/11/4
  • Rating change
    Wolfe Research Upgrades Madrigal Pharmaceuticals(MDGL.US) to Buy Rating, Announces Target Price $605
    Market Newswire · 2026/8/4
  • H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620
    Market Newswire · 2026/11/12
  • Rating change
    CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $612
    Market Newswire · 2026/10/29
  • Rating change
    UBS Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $735
    Market Newswire · 2026/10/15
  • Rating change
    Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $760
    Market Newswire · 2026/11/4
  • Rating change
    BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Cuts Target Price to $533
    Market Newswire · 2026/10/19
  • Rating change
    UBS Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $735
    Market Newswire · 2026/10/14
  • Rating change
    Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $962
    Market Newswire · 2026/8/4
  • Madrigal Pharmaceuticals(MDGL.US) Director Buys US$35.02 Million in Common Stock
    Market Newswire · 2026/11/7
  • Rating change
    Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $709
    Market Newswire · 2026/7/31
  • Rating change
    TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $644
    Market Newswire · 2026/7/31
  • Rating change
    Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725
    Market Newswire · 2026/9/23
  • Rating change
    Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704
    Market Newswire · 2026/9/24
  • Rating change
    CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $612
    Market Newswire · 2026/8/12
  • A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $479 to $743
    Market Newswire · 2026/11/5
  • Rating change
    CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $587
    Market Newswire · 2026/7/29
  • BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $479
    Market Newswire · 2026/11/10
  • Rating change
    Wells Fargo Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $685
    Market Newswire · 2026/7/27
  • Rating change
    Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739
    Market Newswire · 2026/7/17
  • Rating change
    BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542
    Market Newswire · 2026/7/14
  • Rating change
    Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962
    Market Newswire · 2026/9/30
  • Rating change
    UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669
    Market Newswire · 2026/7/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Madrigal Pharmaceuticals discussion 0 comments

Add a comment